|
 |
European Pharmaceutical Contractor
|
In the early 1990s a new phenomenon in the conduction of clinical trials began to emerge. Up until then physicians conducted clinical trials within their own practices. GPs and specialists recruited trial patients from their own databases. However, Good Clinical Practice (GCP) guidelines subsequently became more stringent and physicians involved in day-to-day health care became increasingly reluctant to concentrate on clinical trials.
The concept evolved of an organisation dedicated to conducting clinical trials with specialist physicians and nurses. The organisations were initially called trial management organisations and later became known as site management organisations (SMOs).
They were company-owned sites which had the best control over the specific trial circumstances. Because of this, an SMO had to cover a number of fixed costs such as physicians' and nurses' salaries. As SMOs have to at very least cover their costs in order to stay in business, I have tried to summarise the cost factors and income in this article. This summary is based on a practical evaluation.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
“PACK DIFFERENT” with EMBALLAGE 2008
“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >> |
|
 |
